This scoping review explores the associations between cancer risk, inflammation, and metabolic syndrome (MetS). The study analyzed 20 relevant manuscripts and found connections between MetS, inflammation, and several cancers, including breast cancer, colorectal cancer, esophageal adenocarcinoma, hepatocellular carcinoma (HCC), and cancer in general. MetS is characterized by conditions such as hyperglycemia, hypertension, hypertriglyceridemia, low HDL cholesterol, and increased waist circumference. Individuals with MetS often experience pro-thrombotic and pro-inflammatory conditions, which may contribute to cardiovascular disease, type 2 diabetes mellitus (T2DM), and cancer. MetS is linked to obesity, insulin resistance, and lipolysis, which can lead to increased free fatty acids (FFAs) in the blood and chronic inflammation. These factors may promote cancer progression by altering metabolic pathways, increasing oxidative stress, and modifying immune responses. Inflammation is a key factor in cancer development, as chronic inflammation can lead to cellular changes that promote tumor growth. Inflammatory processes can increase oxidative stress, reduce antioxidant capacity, and damage cellular components, contributing to cancer risk. Inflammatory cytokines such as TNF-α and IL-6 are involved in the progression of cancer and are associated with MetS. Additionally, chronic inflammation can enhance the tumor microenvironment, promoting angiogenesis, invasion, and metastasis. The study also highlights the role of insulin resistance, hyperinsulinemia, and IGF-1 in cancer development. These factors are closely linked to MetS and can contribute to the progression of cancer by promoting cell proliferation and inhibiting apoptosis. The interplay between MetS, inflammation, and cancer is complex, with multiple pathways and mechanisms involved. Prevention strategies, such as dietary changes and lifestyle modifications, may help reduce cancer risk by addressing the underlying factors associated with MetS and inflammation. The review emphasizes the importance of understanding these associations to develop effective prevention and treatment strategies for cancer.This scoping review explores the associations between cancer risk, inflammation, and metabolic syndrome (MetS). The study analyzed 20 relevant manuscripts and found connections between MetS, inflammation, and several cancers, including breast cancer, colorectal cancer, esophageal adenocarcinoma, hepatocellular carcinoma (HCC), and cancer in general. MetS is characterized by conditions such as hyperglycemia, hypertension, hypertriglyceridemia, low HDL cholesterol, and increased waist circumference. Individuals with MetS often experience pro-thrombotic and pro-inflammatory conditions, which may contribute to cardiovascular disease, type 2 diabetes mellitus (T2DM), and cancer. MetS is linked to obesity, insulin resistance, and lipolysis, which can lead to increased free fatty acids (FFAs) in the blood and chronic inflammation. These factors may promote cancer progression by altering metabolic pathways, increasing oxidative stress, and modifying immune responses. Inflammation is a key factor in cancer development, as chronic inflammation can lead to cellular changes that promote tumor growth. Inflammatory processes can increase oxidative stress, reduce antioxidant capacity, and damage cellular components, contributing to cancer risk. Inflammatory cytokines such as TNF-α and IL-6 are involved in the progression of cancer and are associated with MetS. Additionally, chronic inflammation can enhance the tumor microenvironment, promoting angiogenesis, invasion, and metastasis. The study also highlights the role of insulin resistance, hyperinsulinemia, and IGF-1 in cancer development. These factors are closely linked to MetS and can contribute to the progression of cancer by promoting cell proliferation and inhibiting apoptosis. The interplay between MetS, inflammation, and cancer is complex, with multiple pathways and mechanisms involved. Prevention strategies, such as dietary changes and lifestyle modifications, may help reduce cancer risk by addressing the underlying factors associated with MetS and inflammation. The review emphasizes the importance of understanding these associations to develop effective prevention and treatment strategies for cancer.